Search results for "EU ORPHAN DRUG|Positive|Treatment of ovarian cancer" in comments (approximate match)
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
Trabectedin (ET-743) is a marine alkaloid isolated from the Caribbean tunicate Ecteinascidia turbinata. Trabectedin was approved for the treatment of liposarcoma or leiomyosarcoma (USA and Europe) and ovarian cancer (only in Europe). Trabectedin exe...
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
AT-406 (DEBIO-1143, SM-406), is a potent and orally bioavailable Smac mimetic and an antagonist of the inhibitor of apoptosis proteins (IAPs). AT-406 inhibits cancer cell growth in various human cancer cell lines. It has good oral bioavailability in ...
Class (Stereo):
CHEMICAL (ABSOLUTE)
Veliparib (ABT-888) is a potent inhibitor of PARP, has good oral bioavailability, can cross the blood-brain barrier, and potentiates temozolomide, platinums, cyclophosphamide, and radiation in syngeneic and xenograft tumor models. AbbVie is developin...
Class (Stereo):
CHEMICAL (RACEMIC)
Targets:
Imexon (INN, trade name Amplimexon) is a substance that is being studied in the treatment of some types of cancer, including pancreatic, lung, breast, prostate, melanoma, and multiple myeloma. Imexon is a thiol-binding small molecule which induces mi...
Class (Stereo):
CHEMICAL (ACHIRAL)
Cediranib (AZD-2171) is a VEGFR-2 kinase inhibitor which was developed by AstraZeneca for the treatment of cancer. The drug reached the final stage of approval by European Medicines Agency in 2008 under the name Zemfirza (it was recommended to be tak...
